Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

Duomeisu (pegylated liposomal doxorubicin) - CSPC Pharma

pegylated liposomal doxorubicin - Generic mfg.

Trodelvy (sacituzumab govitecan-hziy) - Gilead

Vegzelma (bevacizumab-adcd) - Celltrion, Hikma

gemcitabine - Generic mfg.

carboplatin - Generic mfg.

Avzivi (bevacizumab-tnjn) - Bio-Thera Solutions, Cipla, BeOne Medicines, Biomm, Mega Lifesciences, Sandoz

Avastin (bevacizumab) - Roche

Aybintio (bevacizumab biosimilar) - Samsung, 3SBio, Mundipharma

Avegra (bevacizumab biosimilar) - Biocad

Myocet (non-pegylated liposomal doxorubicin) - Teva, Sopherion

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy (clinicaltrials.gov) - Sep 30, 2026 - P2 | N=87 | Recruiting | Sponsor: National Cancer Institute (NCI) | Initiation date: Jun 2027 ➔ Sep 2026
Platinum sensitive • Trial initiation date • Fallopian Tube Cancer • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor • BRCA1 • BRCA2 • HRD

http://clinicaltrials.gov/ct2/show/NCT07504588

Sep 30, 2026